The HiMed China Accelerator Program is aimed to provide CEOs of medtech & biotech and companies and R&D organizations in the broader healthcare sector with the knowhow to develop a successful innovation and business strategy for China. It includes two-day bootcamp courses and 3-month mentoring services. The two-day of activities will be delivered as a series of presentations, case study ,mentor discussions and workshop forums enabling start-ups to access expert advice on market entry, business strategy, fund raising in China, etc. So far, more than 32 foreigner entrepreneurs have successfully participated in previous classes with over 1/3 of companies reporting back that they have achieved their goals and rapid development and growth for their business.
OncoDX is developing early detection blood tests for ovarian and gastric cancer.Our mission is the early detection of cancer,when it can be cured.
HiMed fund helped to find partner in China and invested 1million yuan to support OncoDX in April 2020.
Medix Biochemica is a world-renowned Finland company, focused on the production and sales of in vitro diagnostic antibodies, there are more than 30 years of research and development and production experience, users around the world. HiMed provided business advisory, corporate formation, Accounting & Tax services for its China R&D and sale WOFE establishment in 2015.